Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial

Keith Copelin Ferdinand, Uri Elkayam, Donna Mancini, Elizabeth Ofili, Ileana L. Pina, Inder Anand, Arthur Michael Feldman, Dennis McNamara, Christopher Leggett

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.

Original languageEnglish (US)
Pages (from-to)151-159
Number of pages9
JournalAmerican Journal of Cardiology
Volume114
Issue number1
DOIs
StatePublished - Jul 1 2014

Fingerprint

Isosorbide Dinitrate
Hydralazine
African Americans
Heart Failure
Enalapril
Mortality
Vasodilator Agents
Nitrates
Guidelines
Morbidity
Exercise Tolerance
Survival
Pharmacogenetics
Dilated Cardiomyopathy
Health Care Costs
Hospitalization
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial. / Ferdinand, Keith Copelin; Elkayam, Uri; Mancini, Donna; Ofili, Elizabeth; Pina, Ileana L.; Anand, Inder; Feldman, Arthur Michael; McNamara, Dennis; Leggett, Christopher.

In: American Journal of Cardiology, Vol. 114, No. 1, 01.07.2014, p. 151-159.

Research output: Contribution to journalArticle

Ferdinand, Keith Copelin ; Elkayam, Uri ; Mancini, Donna ; Ofili, Elizabeth ; Pina, Ileana L. ; Anand, Inder ; Feldman, Arthur Michael ; McNamara, Dennis ; Leggett, Christopher. / Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial. In: American Journal of Cardiology. 2014 ; Vol. 114, No. 1. pp. 151-159.
@article{f2cf2310f0b9460490aa28df28e0413b,
title = "Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial",
abstract = "The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.",
author = "Ferdinand, {Keith Copelin} and Uri Elkayam and Donna Mancini and Elizabeth Ofili and Pina, {Ileana L.} and Inder Anand and Feldman, {Arthur Michael} and Dennis McNamara and Christopher Leggett",
year = "2014",
month = "7",
day = "1",
doi = "10.1016/j.amjcard.2014.04.018",
language = "English (US)",
volume = "114",
pages = "151--159",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial

AU - Ferdinand, Keith Copelin

AU - Elkayam, Uri

AU - Mancini, Donna

AU - Ofili, Elizabeth

AU - Pina, Ileana L.

AU - Anand, Inder

AU - Feldman, Arthur Michael

AU - McNamara, Dennis

AU - Leggett, Christopher

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.

AB - The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.

UR - http://www.scopus.com/inward/record.url?scp=84902141731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902141731&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2014.04.018

DO - 10.1016/j.amjcard.2014.04.018

M3 - Article

VL - 114

SP - 151

EP - 159

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -